15 22

Cited 0 times in

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Authors
 Shiv K Sarin  ;  Manoj Kumar  ;  Mohammed Eslam  ;  Jacob George  ;  Mamun Al Mahtab  ;  Sheikh M Fazle Akbar  ;  Jidong Jia  ;  Qiuju Tian  ;  Rakesh Aggarwal  ;  David H Muljono  ;  Masao Omata  ;  Yoshihiko Ooka  ;  Kwang-Hyub Han  ;  Hye Won Lee  ;  Wasim Jafri  ;  Amna S Butt  ;  Chern H Chong  ;  Seng G Lim  ;  Raoh-Fang Pwu  ;  Ding-Shinn Chen 
Citation
 LANCET GASTROENTEROLOGY & HEPATOLOGY, Vol.5(2) : 167-228, 2020-02 
Journal Title
LANCET GASTROENTEROLOGY & HEPATOLOGY
Issue Date
2020-02
MeSH
Asia / epidemiology ; Gastroenterology* ; Humans ; Liver Diseases / epidemiology* ; Morbidity / trends ; Pacific Islands / epidemiology ; Periodicals as Topic* ; Prognosis ; Survival Rate / trends
Abstract
The Asia-Pacific region is home to more than half of the global population and accounted for 62.6% of global deaths due to liver diseases in 2015. 54.3% of global deaths due to cirrhosis, 72.7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute viral hepatitis occurred in this region in 2015. Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20.8%), non-alcoholic fatty liver disease (NAFLD; 12.1%), and chronic infection with hepatitis C virus (HCV; 15.7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. Preventive strategies for viral hepatitis-related liver disease include increasing access to clean drinking water and sanitation. HBV vaccination programmes for neonates have been implemented by all countries, although birthdose coverage is extremely suboptimal in some. Availability of screening tests for blood and tissue, donor recall policies, and harm reduction strategies are in their initial stages in most countries. Many governments have put HBV and HCV drugs on their essential medicines lists and the availability of generic versions of these drugs has reduced costs. Efforts to eliminate viral hepatitis as a public health threat, together with the rapid increase in per-capita alcohol consumption in countries and the epidemic of obesity, are expected to change the spectrum of liver diseases in the Asia-Pacific region in the near future. The increasing burden of alcohol-related liver diseases can be contained through government policies to limit consumption and promote less harmful patterns of alcohol use, which are in place in some countries but need to be enforced more strictly. Steps are needed to control obesity and NAFLD, including policies to promote healthy lifestyles and regulate the food industry. Inadequate infrastructure and insufficient health-care personnel trained in liver diseases are issues that also need to be addressed in the Asia-Pacific region. The policy response of most governments to liver diseases has thus far been inadequate and poorly funded. There must be a renewed focus on prevention, early detection, timely referral, and research into the best means to introduce and improve health interventions to reduce the burden of liver diseases in the Asia-Pacific region.
Files in This Item:
T9992020477.pdf Download
DOI
10.1016/S2468-1253(19)30342-5
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190252
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links